Cysteine dioxygenase (CDO) and cysteamine (2-aminoethanethiol) dioxygenase (ADO) are the only known mammalian thiol dioxoygenase (TDO) enzymes. TDO enzymes use a single Fe(II) ion within their active site to catalyze the oxygen-dependent oxidation of sulfur-bearing amino acid derivatives without the need for an external electron source. Of the TDO enzymes, mammalian CDO is the best characterized. Until recently, the catabolic dissimilation of L-cysteine to produce inorganic sulfate, pyruvate, hypotaurine, and taurine was believed to be unique within the domain of eukaryotics. However, a number of bacterial TDO enzymes have now been identified, suggesting that the ability to oxidize excess thiols is advantageous for survival. Indeed, the biochemistry associated with sulfur metabolism has increasingly become relevant for the development of pathogenic drug targets as well as therapies for cancer and inflammatory disease. In mammals, imbalances in sulfur metabolism are frequently used as a biomarker for the identification of neurological and autoimmune disorders, such as Autism, and Parkinson’s, Alzheimer’s disease.
Currently, the Pierce group is working toward the development of a mechanistic model for sulfur-oxidation catalyzed by TDO enzymes. An integrated biophysical/inorganic approach is applied to the study of these enzymes, relying on techniques such as steady-state and pre-steady state kinetics, site-directed mutagenesis, mass spectrometry, UV-visible, and EPR spectroscopy.